As demonstrated in Figure 1, absolute 5-year OS was worse amongst patients with LA-HR+/HER2- BC in the entire cohort (89.4% vs. 92.2%) and essentially identical in those receiving appropriate treatment (94.2% vs. 94.5%). Here, ERBB2 is linked to breast cancer.